Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. It is grouped under the following drug class(es): Antineoplastic agents and Kinase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Dacomitinib hydrate and Vizimpro. Its PubChem CID is 70693519.
Dacomitinib monohydrate
| CAS No | 1042385-75-0 |
|---|---|
| Molecular Formula | C24H27ClFN5O3 |
| Molecular Weight | 488.0 g/mol |
| Synonyms | (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
The listed CAS number is 1042385-75-0.
The listed molecular formula is C24H27ClFN5O3.
The listed molecular weight is 488.0 g/mol.
(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide;hydrate.
The source lists Dacomitinib hydrate and Vizimpro.